Oral Drug Danegaptide Shows Potential to Protect Against Diabetic Eye Disease

Danegaptide, an oral drug, has shown promise in preventing or slowing the progression of diabetic retinopathy, a condition that can cause vision loss in people with diabetes. This development could offer a new approach to managing vision-threatening damage associated with the disease.

Originally published by gnews